Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression (Q33376149)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression |
scientific article |
Statements
1 reference
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression (English)
1 reference
Anna Dmoszynska
1 reference
Pieter Sonneveld
1 reference
Robert Z Orlowski
1 reference
Tadeusz Robak
1 reference
Arnon Nagler
1 reference
Joan Bladé
1 reference
Roman Hajek
1 reference
Andrew Spencer
1 reference
Jesús San Miguel
1 reference
Noemi Horvath
1 reference
Heather J Sutherland
1 reference
Alexander N Suvorov
1 reference
Sen H Zhuang
1 reference
Trilok Parekh
1 reference
Liang Xiu
1 reference
Zhilong Yuan
1 reference
Wayne Rackoff
1 reference
Jean-Luc Harousseau
1 reference
1 reference
Identifiers
1 reference